Rheumatoid Arthritis Clinical Trial
Official title:
Prospective Validation of Soluble Biomarkers as Predictors of Structural Damage in Rheumatoid Arthritis
NCT number | NCT01476956 |
Other study ID # | RA BIODAM |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | October 2011 |
Est. completion date | December 31, 2019 |
Verified date | October 2021 |
Source | Canadian Research & Education in Arthritis |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Recruited patients will include those about to begin Disease-Modifying Antirheumatic Drug) DMARD therapy or about to change DMARD therapy. Disease activity will be monitored systematically every 3 months by the Disease Activity Score. Changes in standard DMARD and/or anti-Tumor Necrosis Factor α (anti-TNFα) therapy will be made according to specific recommendations for patients receiving these therapies. Biomarker samples will be collected every 3 months and prior to change in DMARD and/or anti-TNF therapy as defined below. A blood sample (40 ml) for serum will be taken for biomarker studies and processed according to the international committee of Outcome Measures in Rheumatology (OMERACT) recommendations for the minimal handling of biomarker samples. A urine sample (20 ml) will also be taken and processed as for serum. Radiography (X-rays) will be conducted every 6 months (baseline, 6, 12, 18, 24 months). Patients will be followed for 2 years.
Status | Completed |
Enrollment | 571 |
Est. completion date | December 31, 2019 |
Est. primary completion date | December 31, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria (selected): - 18 years of age or older - RA according to the 2010 Rheumatoid Arthritis Classification Criteria - Joint symptoms for = 3 months prior to screening - DAS44 > 2.4 - About to start DMARD therapy (methotrexate, salazopyrin, hydroxychloroquine, chloroquine, leflunomide) or - increased dose of methotrexate by =10 mg weekly to a maximum dose of 25mg weekly (if already receiving >15mg will require add-on DMARD/anti-TNF or switch to alternative DMARD), - add-on of alternative DMARD, - switch to alternative DMARD, - start of first anti-TNFa agent (adalimumab, etanercept, infliximab, certolizumab pegol, golimumab) - If already on DMARD therapy this has been stable for the 3 months prior to the baseline visit - If already on systemic steroid, dose must be stable (prednisone = 7.5mg/day) for 1 month prior to the baseline visit - Patient will be available for follow up for a minimum of 24 months from the baseline visit Exclusion Criteria (selected): - Intra-articular steroid injection within 4 weeks prior to the baseline visit - Prior treatment with anti-TNFa or other biological agent (rituximab, abatacept, tocilizumab) - Malignancy within past 5 years (other than basal cell carcinoma that has been adequately treated or excised, squamous cell cancer of the skin, and cervical carcinoma in situ) - History of: - Serious infection (defined as requiring parenteral antibiotics or hospitalization) within 3 months prior to the baseline visit; - Active tuberculosis or history of tuberculosis without documented curative treatment and/or positive tuberculin reaction to PPD (Purified Protein Derivative) - For patients starting anti-TNF therapy, a positive TB screening test and no record of effective prophylaxis according to local expert recommendations - Known infection with Human Immunodeficiency Virus (HIV), Hepatitis B or Hepatitis C |
Country | Name | City | State |
---|---|---|---|
Canada | University of Calgary | Calgary | Alberta |
Canada | Division of Rheumatology, University of Alberta Hospital | Edmonton | Alberta |
Canada | The Arthritis Research Group | Newmarket | Ontario |
Canada | Saskatoon Osteoporosis Centre | Saskatoon | Saskatchewan |
Canada | University of Sherbrooke | Sherbrooke | Quebec |
Canada | Memorial University | St. John's | Newfoundland and Labrador |
Canada | Arthritis Center, University of Manitoba | Winnipeg | Manitoba |
Denmark | Department of Rheumatology, Copenhagen University Hospital at Glostrup | Glostrup | |
France | Service de Rheumatologie-CHU Bordeaux Pellegrin | Bordeaux | |
France | Le Roux Liana, Centre d'Investigation Clinique | Brest | |
France | Centre des Consultations et imagerie de l'appareil locomoteur service de rheumatologie | Lille | |
France | Departement de rheumatologie, Hopital Lapeyronie | Montpellier | |
France | Rheumatologie B, Hopital Cochin | Paris | |
France | Infirmiere de Recherche Clinique, CHU de Toulouse, Centre de Rheumatologie, Hopital Purpan | Toulouse | |
Germany | Kerckhoff-Klinik, Department of Rheumatology and Clinical Immunology | Bad Nauheim | |
Germany | Department of Rheumatology/Clinical Immunology, Medizinische Klinik-Rheumatologie und Klinische Immunologie | Berlin | |
Germany | Universitatsklinikum der Friedrich-Schiller-Universitat Jena, Klinik für Innere Medizin III/Rheumatologie/Osteologie | Jena | |
Germany | Dr Spieler | Zerbst | |
Ireland | Department of Rheumatology, St. Vincents University Hospital | Dublin | |
Israel | Tel Aviv Sourasky Medical Centre | Tel Aviv | |
Italy | University of Ferrara | Ferrara | |
Italy | University of Milan | Milan | |
Italy | Day Hospital Reumatologia | Milano | |
Italy | University of Padova | Padova | |
Italy | Catholic University of the Sacred Heart | Rome | |
Italy | Department of Rheumatology, University of Verona | Verona | |
Netherlands | Academic Medical Centre/University of Amsterdam | Amsterdam | |
Netherlands | Amsterdam VU University Medical Centre | Amsterdam | |
Netherlands | Academic Medical Centre/University of Amsterdam and Atrium Medical Centre Heerlen | Heerlen | |
Netherlands | Afdeling Reumatologie, Leids Universitair Medisch Centrum | Leiden | |
Norway | Department of Rheumatology, Diakonhjemmet Hospital | Oslo | |
United States | Johns Hopkins Arthritis Center, Johns Hopkins University | Baltimore | Maryland |
United States | Division of Rheumatology, Columbia University, College of Physicians and Surgeons | New York | New York |
United States | Rheumatologist Hospital for Special Surgery | New York | New York |
United States | Division of Allergy, Immunology and Rheumatology, University of Rochester | Rochester | New York |
United States | Seattle Rheumatology Associates | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
Canadian Research & Education in Arthritis | Abbott |
United States, Canada, Denmark, France, Germany, Ireland, Israel, Italy, Netherlands, Norway,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To determine the independent predictive validity of several soluble biomarkers for predicting structural damage in Rheumatoid Arthritis (RA). | 24 Months | ||
Secondary | To establish which modifiable clinical and laboratory predictors used in routine practice individually and in combination, have the strongest and the most consistent association with change in radiographic damage in patients on standard RA therapy. | 24 Months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04226131 -
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
|
N/A | |
Completed |
NCT04171414 -
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT02833350 -
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
|
Phase 2 | |
Completed |
NCT04255134 -
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
|
Phase 4 | |
Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT03514355 -
MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms
|
N/A | |
Recruiting |
NCT06005220 -
SBD121, a Synbiotic Medical Food for RA Management
|
N/A | |
Recruiting |
NCT05451615 -
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT05054920 -
Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT02037737 -
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
|
N/A | |
Recruiting |
NCT04079374 -
Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel
|
Phase 3 | |
Completed |
NCT02504268 -
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
|
Phase 3 | |
Recruiting |
NCT05496855 -
Remote Care in People With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06103773 -
A Study of Single and Multiple Oral Doses of TollB-001
|
Phase 1 | |
Recruiting |
NCT06031415 -
Study of GS-0272 in Participants With Rheumatoid Arthritis
|
Phase 1 | |
Completed |
NCT05999266 -
The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
|
||
Recruiting |
NCT05302934 -
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
|
||
Recruiting |
NCT04169100 -
Novel Form of Acquired Long QT Syndrome
|
Phase 4 |